Navigation Links
/C O R R E C T I O N - Mindray Medical International Limited /
Date:9/3/2010

/C O R R E C T I O N - Mindray Medical... -- SHENZHEN, China, Aug. 25 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Trade Show News Click to view news release full screen  

/C O R R E C T I O N - Mindray Medical International Limited /

   

In the news release, "Mindray Medical to Present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference," issued Wednesday, August 25, by Mindray Medical International Limited (NYSE: MR) over PR Newswire Asia, we are advised by the company that Mr. Ronald Ede, instead of both Mr. Ronald Ede and Mr. Minghe Cheng, will attend the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference, as originally issued inadvertently. The complete, corrected release follows.Mindray Medical to Present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference

SHENZHEN, China, Aug. 25 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference in London on September 8th, 2010. Mr. Ronald Ede will present on behalf of Mindray.

The Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference will be attended by Mr. Ronald Ede, Mindray's chief financial officer. The conference will take place at Goldman Sachs' offices, located at 120 Fleet Street in London, UK, from Wednesday, September 8th to Thursday, September 9th, 2010. Mr. Ronald Ede will present on Wednesday, September 8th at 01:45 pm GMT.

About Mindray

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global operational headquarters in Shenzhen, China, and multiple sales offices in major domestic and international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://ir.mindray.com.

For investor and media inquiries please contact: In the US: John Capodanno FD Tel: +1-212-850-5705 Email: john.capodanno@fd.com Bryan Armstrong FD Tel: +1-312-553-6707 Email: bryan.armstrong@fd.com In China: Cathy Gao Tel: +86-755-2658-2518 Email: ir@mindray.com
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
2. Mindray Medical to Present at J.P. Morgan China Conference 2010
3. Mindray Medical Provides Mid-Year Update on Product Development
4. Mindray to Report Second Quarter 2010 Financial Results on August 9, 2010
5. Mindray to Attend the 2010 American Association for Clinical Chemistry Conference
6. Mindray Launches New Premium M7 Portable Ultrasound System in U.S.
7. Mindray Medical to Present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference
8. Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
(Date:12/8/2016)... , Dec. 8, 2016 A Small ... the National Institutes of Health (NIH) to ... University.  The grant will seek to ... head device, which utilizes electromagnetic waves to treat Alzheimer,s ... this novel technology to possibly treat other neurologic disorders ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):